June 2, 2023Open Access
Design and rationale of the MODULAR ATP global clinical trial: A novel intercommunicative leadless pacing system and the subcutaneous implantable cardioverter-defibrillator
Key Result
The MODULAR ATP trial aims to prospectively validate the safety and efficacy of a novel intercommunicating leadless pacing system with the S-ICD.
Structured PICO
I
Intervention
Intercommunicating leadless pacing system with the subcutaneous implantable cardioverter-defibrillator (S-ICD)
O
Outcome
Safety and efficacy (device-device communication, pacing performance, rate responsiveness, and system safety)
The MODULAR ATP trial is designed to evaluate the safety and efficacy of a novel intercommunicating leadless pacing system combined with a subcutaneous ICD.
Main Result
Absolute Event Rate: 0% vs 0%
Abstract
The MODULAR ATP global clinical trial will prospectively test the safety and efficacy of the first intercommunicating leadless pacing system with the S-ICD. This trial will allow for robust validation of device-device communication, pacing performance, rate responsiveness, and system safety.
Cite This Study
Lloyd et al. (Fri,) reported a other. The MODULAR ATP trial aims to prospectively validate the safety and efficacy of a novel intercommunicating leadless pacing system with the S-ICD.